Unibest

Pharmaceutical intermediates

Trofinetide Intermediates

2 pharmaceutical intermediates for Trofinetide. Indication: Rett Syndrome.

提交项目All intermediates

About Trofinetide

Originator
Walter Reed Army Institute; Polynovo; Neuren Pharmaceuticals Ltd
Indication
Rett Syndrome
Approved Date
03/10/2023
NCE Patent
03/10/2028
DS/DP
01/27/2032

Available intermediates

2 intermediates currently listed for Trofinetide. Request specifications, documentation or a quotation for any item below.

Trofinetide intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(S)-2-Methylproline42856-71-3//
2-Methyl-L-proline Methyl ester hydrochloride220060-08-2//

Other programs under T

Tazemetostat HydrobromideTazobactam SodiumTegoprazanTenapanor HydrochlorideTeneligliptinTetrabenazineTezacaftorTianeptine sodium salt

Building toward Trofinetide?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →